Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice.

Original publication

DOI

10.1093/qjmed/hcq017

Type

Journal article

Journal

QJM

Publication Date

06/2010

Volume

103

Pages

367 - 377

Keywords

Drug Evaluation, Preclinical, Hemorrhage, Humans, Piperazines, Platelet Aggregation Inhibitors, Prasugrel Hydrochloride, Purinergic P2 Receptor Antagonists, Randomized Controlled Trials as Topic, Receptors, Purinergic P2, Risk Factors, Thiophenes, Ticlopidine